Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing

BACKGROUND/AIMS: Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge. METHODS: We developed a rituximab-resistant cell line (RRCL) by sequential exposure to gradually increasin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Min Ji, Yu, Eun Sang, Choi, Chul Won, Kim, Dae Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636549/
https://www.ncbi.nlm.nih.gov/pubmed/37599392
http://dx.doi.org/10.3904/kjim.2023.134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636549/
https://www.ncbi.nlm.nih.gov/pubmed/37599392
http://dx.doi.org/10.3904/kjim.2023.134

Ejemplares similares